Results 1 to 10 of about 3,726 (180)

Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study [PDF]

Rheumatology and Therapy
Introduction The aim of this work was to evaluate the achievement of minimal clinically important improvement (MCII) in patient-reported outcomes (PROs) with guselkumab among participants with active psoriatic arthritis (PsA) and inadequate response to ...
Laure Gossec, Xenofon Baraliakos, James Galloway, Vilija Oke, Petros Sfikakis, Emmanouil Rampakakis, Mohamed Sharaf, Frederic Lavie, Iain B. McInnes   +8 more
doaj   +2 more sources

Efficacy and safety of Guselkumab for moderate-to-severe psoriasis: A systematic review and meta-analysis of randomized controlled trials [PDF]

Dermatology Practical & Conceptual
Introduction: Psoriasis, a chronic inflammatory skin condition, affects 125 million worldwide. Current treatments provide symptomatic relief but face limitations. Guselkumab shows promise for moderate-to-severe psoriasis.
Laura Ghanem, Antonia Moubarak, Jacinthe Khater, Ibrahim A. Yakout, Virginia Velasco-Tamariz   +4 more
doaj   +2 more sources

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors [PDF]

Rheumatology and Therapy
Introduction There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (
Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F. Merola   +13 more
doaj   +2 more sources

Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn’s disease: Report and systematic literature review of effectiveness and safety

Clinical Case Reports (discontinued), 2020
Guselkumab appears to be safe and effective in the treatment of patients with HS, who do not respond to adalimumab and other systemic therapies. Guselkumab can be used in patients with comorbid Crohn's disease.
Astrid-Helene Ravn Jørgensen, Jesper Grønlund Holm, Simon Francis Thomsen   +2 more
exaly   +2 more sources

Guselkumab Treatment ADHEREnce in BulGaria of Patients with Psoriasis—ADHERE-BG Study [PDF]

Dermatology and Therapy
Introduction Treatment adherence is crucial for managing chronic diseases, including plaque psoriasis. In Bulgaria, patients with plaque psoriasis can receive treatment with reimbursed biologics, such as guselkumab, if they meet National Health Insurance
Grisha S. Mateev, Zdravka V. Demerdjieva, Rumyana K. Yankova, Klimentina D. Gospodinova, Boryana E. Ilieva, Razvigor B. Darlenski   +5 more
doaj   +2 more sources

Guselkumab - In Psoriasis and Beyond

Dermatology Practical & Conceptual
Introduction: Guselkumab is an interleukin 23p19 inhibitor, and the first in this group, to be approved by the US Food and Drug Administration (FDA) for the management of moderate to severe psoriasis.
Aditya Kumar Bubna, Vinayak Viplav
doaj   +3 more sources

Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials [PDF]

Rheumatology and Therapy
Introduction Psoriatic arthritis (PsA) is a heterogeneous disease, and clinical manifestations can differ between sexes. Sex-disaggregated baseline characteristics, guselkumab efficacy, and radiographic progression were assessed in a pooled cohort of ...
Dafna D. Gladman, Lihi Eder, Carlo Selmi, Philip J. Mease, Alexis Ogdie, Karissa Lozenski, Elizabeth Adamson, Mohamed Sharaf, Emmanouil Rampakakis, Laura Pina Vegas, Laura C. Coates   +10 more
doaj   +2 more sources

Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis

Clinical and Translational Science, 2022
Guselkumab is an anti‐interleukin‐23 human monoclonal antibody effective in treating psoriatic arthritis (PsA). To characterize the pharmacokinetics (PKs) and exposure‐response relationship of guselkumab in PsA, population PKs, and exposure‐response ...
Yang Chen, Xin Miao, Chyi‐Hung Hsu, Yanli Zhuang, Alexa Kollmeier, Zhenhua Xu, Honghui Zhou, Amarnath Sharma   +7 more
doaj   +1 more source

Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial

Arthritis Research & Therapy, 2023
Background Nail psoriasis is a common, physiologically, and psychologically disruptive, and yet often under-treated manifestation of psoriasis. The objectives of this analysis were to investigate the trajectory of nail psoriasis, a risk factor for ...
William Tillett, Alexander Egeberg, Enikö Sonkoly, Patricia Gorecki, Anna Tjärnlund, Jozefien Buyze, Sven Wegner, Dennis McGonagle   +7 more
doaj   +1 more source

Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis

Acta Dermato-Venereologica, 2022
Guselkumab treatment outcomes and persistence were assessed in a real-world cohort of Finnish patients with difficult-to-treat plaque psoriasis over a median follow-up of 1 year.
Tarja Mälkönen, Pauliina Nuutinen, Taru Hallinen, Erkki Soini, Riikka Nissinen, Christina Wennerstöm, Tapio Rantanen, Johanna H. Hagman, Rauno Harvima, Johanna Höök-Nikanne, Tiina Ilves, Päivi Lintu, Ken Malanin, Iina Soramäki, Kaisa Tasanen, Arja Teho, Katja Vähävihu, Sari Itälinna, Pekka Leinonen, Piia Sarajärvi, Laura Huilaja, Rafael Pasternack   +21 more
doaj   +1 more source